Novo Nordisk A/S (NVO)
123.06
-0.96
(-0.77%)
USD |
NYSE |
May 03, 16:00
123.00
-0.06
(-0.05%)
After-Hours: 18:11
Novo Nordisk Accounts Payable (Quarterly): 1.881B for March 31, 2024
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.881B |
December 31, 2023 | 3.802B |
September 30, 2023 | 2.848B |
June 30, 2023 | 2.596B |
March 31, 2023 | 1.471B |
December 31, 2022 | 2.243B |
September 30, 2022 | 1.098B |
June 30, 2022 | 2.057B |
March 31, 2022 | 1.002B |
December 31, 2021 | 1.350B |
September 30, 2021 | 1.385B |
June 30, 2021 | 1.219B |
March 31, 2021 | 1.072B |
December 31, 2020 | 944.93M |
September 30, 2020 | 965.44M |
June 30, 2020 | 1.352B |
March 31, 2020 | 789.23M |
December 31, 2019 | 953.20M |
September 30, 2019 | 863.71M |
June 30, 2019 | 802.70M |
March 31, 2019 | 634.48M |
December 31, 2018 | 1.035B |
September 30, 2018 | 753.99M |
June 30, 2018 | 904.35M |
March 31, 2018 | 680.62M |
Date | Value |
---|---|
December 31, 2017 | 904.05M |
September 30, 2017 | 717.01M |
June 30, 2017 | 654.85M |
March 31, 2017 | 543.28M |
December 31, 2016 | 854.82M |
September 30, 2016 | 671.53M |
June 30, 2016 | 797.39M |
March 31, 2016 | 568.63M |
December 31, 2015 | 721.71M |
September 30, 2015 | 579.98M |
June 30, 2015 | 591.10M |
March 31, 2015 | 581.91M |
December 31, 2014 | 808.19M |
September 30, 2014 | 509.33M |
June 30, 2014 | 546.65M |
March 31, 2014 | 642.61M |
December 31, 2013 | 757.39M |
September 30, 2013 | 530.31M |
June 30, 2013 | 506.89M |
March 31, 2013 | 529.19M |
December 31, 2012 | 683.97M |
September 30, 2012 | 465.60M |
June 30, 2012 | 442.17M |
March 31, 2012 | 458.11M |
December 31, 2011 | 573.49M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
789.23M
Minimum
Mar 2020
3.802B
Maximum
Dec 2023
1.535B
Average
1.285B
Median
Accounts Payable (Quarterly) Benchmarks
Amgen Inc | 1.59B |
AstraZeneca PLC | 19.70B |
Vertex Pharmaceuticals Inc | 364.90M |
Viking Therapeutics Inc | 5.225M |
Evaxion Biotech AS | 2.689M |